Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3339277 | 0.89 | TSHR (0.67) | TSHRGLAKMT2AGAAKDM4E | |
| SCHEMBL4172039 | 0.89 | TSHR (0.67) | TSHRGLAKMT2AMEN1GAA | |
| SCHEMBL314589 | 0.89 | TSHR (0.75) | TSHRGLAKMT2AMEN1GAA | |
| SCHEMBL6973124 | 0.89 | GAA (0.73) | TSHRGLAKMT2AMEN1GAA | |
| SCHEMBL4598393 | 0.88 | TSHR (0.66) | TSHRGLAKMT2AMEN1GAA | |
| SCHEMBL19829315 | 0.87 | TSHR (0.69) | TSHRGLAKMT2AGAAKDM4E | |
| SCHEMBL6504430 | 0.87 | KMT2A (0.74) | TSHRGLAKMT2AMEN1GAA | |
| SCHEMBL4468382 | 0.85 | GAA (0.64) | TSHRGLAKMT2AMEN1GAA | |
| SCHEMBL12569718 | 0.84 | TSHR (0.68) | TSHRGLAKMT2AGAAKDM4E | |
| SCHEMBL12911161 | 0.82 | TSHR (0.69) | TSHRGLAKMT2AGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507484-B2 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8507484-B2 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | KYOWA KIRIN CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213361-A1 | Preventive and/or therapeutic agent for neutrophilic inflammatory diseases | MPO, MSR1, NR4A3 | TSHR 2733/4885GLA 1215/4885KMT2A 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.